BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Zhimeng Biopharma Secures China’s Green Light for Phase 2 Trial of Next-Gen Epilepsy Drug CB03-154

Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, ...

September 12, 2025 | News

Cytiva and WhiteLab Genomics Partner to Accelerate AAV Genomic Medicine Development

Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timelin...

September 11, 2025 | News

XtalPi and PharmaEngine Advance AI-Designed PRMT5 Inhibitor PEP08 into Phase 1 Trials for Solid Tumours

XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaborati...

September 10, 2025 | News

Evonik and Ethris Forge Strategic Alliance to Advance Next-Generation Lipid Nanoparticle Delivery

Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, ...

September 10, 2025 | News

Samsung Biologics Expands Presence in Japan with New Tokyo Office

Samsung Biologics has announced the opening of a new office in Tokyo, underscoring its long-term commitment to supporting Japan’s pharmaceutical and ...

September 09, 2025 | News

KBI Biopharma and Infinimmune Partner to Advance Manufacturing of Lead Human-First Antibody IFX-101

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotec...

September 09, 2025 | News

Servier Acquires Kaerus Bioscience’s KER-0193 in Deal Worth Up to $450M

Servier, an independent international pharmaceutical group governed by a foundation, announced that it has entered into a definitive agreement with Kaerus ...

September 09, 2025 | News

Takeda Wins U.S. FDA Approval to Expand VONVENDI Use in Adults and Children with Von Willebrand Disease

Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce the Frequency of Bleeding Episodes in Adults with Type 1 and 2 Von Willebrand D...

September 08, 2025 | Regulatory

AstraZeneca’s FLAURA2 Trial Confirms TAGRISSO Plus Chemotherapy Extends Survival in EGFR-Mutated Lung Cancer

FLAURA2 final overall survival analysis reinforces the favorable benefit-risk profile of this combination Results underscore TAGRISSO as 1st-line s...

September 08, 2025 | News

Taiwan’s Senhwa Biosciences Gains FDA IND Clearance for CX-5461 in MYC-Driven B-Cell Lymphomas

Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has gran...

September 08, 2025 | News

Huadong Medicine Reports Promising Phase I Results for Novel ROR1-Targeting ADC HDM2005 in Lymphoma

Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine") announced positive preliminary results from a Phase I study of HDM2005, an...

September 08, 2025 | News

Andelyn Biosciences and Tern Therapeutics Partner to Advance Gene Therapy for CLN2 Batten Disease

Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...

September 08, 2025 | News

Stallergenes Greer and Nuance Pharma Enter Exclusive Partnership to Develop and Commercialise Actair® in China

Stallergenes Greer, a global leader in allergy therapeutics, and Nuance Pharma, an innovation-focused biopharmaceutical company based in China, announced t...

September 05, 2025 | News

China’s Biocytogen and Germany’s Merck KGaA Join Forces on Antibody-LNP Delivery Innovation

-Biocytogen Pharmaceuticals , a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative te...

September 05, 2025 | News

Stay Connected